Methamphetamine (METH) is a powerful psychostimulant drug used worldwide for its reinforcing properties. In addition to the classic long-lasting monoaminergic-disrupting effects extensively described in the literature, METH has been consistently reported to increase blood brain barrier (BBB) permeability, both in vivo and in vitro, as a result of tight junction and cytoskeleton disarrangement. Microtubules play a critical role in cell stability, which relies on post-translational modifications such as a-tubulin acetylation. As there is evidence that psychostimulants drugs modulate the expression of histone deacetylases (HDACs), we hypothesized that in endothelial cells METH-mediation of cytoplasmatic HDAC6 activity could affect tubulin acetylation and further contribute to BBB dysfunction. To validate our hypothesis, we exposed the bEnd.3 endothelial cells to increasing doses of METH and verified that itleads to an extensivea-tubulin deacetylation mediated by HDACs activation. Furthermore, since we recently reported that acetyl-L-carnitine (ALC), a natural occurring compound, prevents BBB structural loss in a context of METH exposure, we reasoned that ALC could also preserve the acetylation of microtubules under METH action. The present results confirm that ALC is able to prevent METH-induced deacetylation providing effective protection on microtubule acetylation. Although further investigation is still needed, HDACs regulation may become a new therapeutic target for ALC.
Introduction Methamphetamine (METH) is a powerful psychostimulant used worldwide
for its reinforcing properties that leads to long-lasting deleterious effects (Gold et al., 2009; Krasnova and Cadet, 2009 ). METH toxicity is characterized by the disruption of the dopaminergic system, concomitant with terminal degeneration and eventual neuronal death (Conant et al., 2011; Krasnova and Cadet, 2009 ). However, METH has been increasingly recognized to impact also the blood-brain-barrier (BBB), causing the release of inflammatory mediators and astrogliosis (Gold et al., 2009; Goncalves et al., 2010; Northrop and Yamamoto, 2012; Ramirez et al., 2009) . METH-induced permeability at the BBB level has been consistently reported both in vivo and in vitro (Conant et al., 2011; Martins et al., 2011; Urrutia et al., 2013) , as a result of tight junction and cytoskeleton disarrangement (Dietrich, 2009; Kousik et al., 2012; Park et al., 2013) . In endothelial cells, METH was also shown to trigger nitric oxide (NO)-mediated transcytosis (Martins et al., 2013) . Recently, we showed, also in endothelial cells, that exposure to METH leads to disruption of actin filaments concomitant with claudin-5 translocation to the cytoplasm, promoted by MMP-9 activation in association with ILK overexpression (Fernandes et al., 2014) . Similarly to the actin filaments, microtubules play a critical role in cell stability and dynamics. Proper regulation of microtubule components relies on post translational modifications such as a-tubulin acetylation (Hammond et al., 2008) . Microtubule deacetylation is carried out by histone deacetylase (HDAC) 6, a class II HDAC and the class III HDAC sirtuin 2 (SIRT2), which form a complex that allows them to bind to tubulin (Hubbert et al., 2002; Nahhas et al., 2007; Sadoul et al., 2011; Yang and Seto, 2008) . Of note, it was recently shown that interfering with HDAC6 is sufficient to prevent microtubule deacetylation (Gold et al., 2015) . There is growing evidence that HDACs inhibition is strongly associated with decreased cell mobility, which is of particular interest in the oncology field (Hrabeta et al., 2014; Ocker and Schneider-Stock, 2007) . Although there are several studies showing that METH and other psychostimulants affect the expression of HDACs (Cassel et al., 2006; Host et al., 2011; Martin et al., 2012; Omonijo et al., 2014) , and in particular the expression of HDAC6 (Omonijo et al., 2014) , the effect of METH in microtubules acetylation was not yet explored. Therefore, we hypothesized that METH-induced regulation of HDACs activity, and in particular of HDAC6, may also mediate the structural loss observed in METH-exposed endothelial cells. Moreover, since we recently showed that a pretreatment with acetyl-L-carnitine (ALC) was able to prevent METH-induced activation of MMP-9, preserving the actin structural arrangement in the endothelial cells (Fernandes et al., 2014) , and ALC was shown to have the potential to interact with HDAC activity (Huang et al., 2012) , we reasoned that ALC could also preserve the acetylation of microtubules under METH action. ALC is a natural occurring compound that was seen to be protective by different mechanisms in several neurological conditions, including BBB dysfunction (Alves et al., 2009; Haorah et al., 2011; Muneer et al., 2011; Pettegrew et al., 2000) . To verify our hypothesis, we exposed the endothelial cell line bEnd.3 to increasing doses of METH and evaluated the individual and combined action of METH and ALC on a-tubulin acetylation. Trichostatin A (TSA), a natural product isolated from Streptomyces hygroscopicus commonly used as an inhibitor of class I/II HDACs known to promote microtubule acetylation, was also assayed (Dompierre et al., 2007; Harrison and Dexter, 2013 MO, . Immortalized bEnd.3 cells at confluence were treated with 0.5 mM and 1 mM of METH. METH doses were predetermined in our laboratory in agreement with previous studies using METH in similar cell models (Fernandes et al., 2014; Jin et al., 2002) . ALC 1 mM was added 30 min before METH. TSA was used in a 100 nM concentration. The selected TSA and ALC doses were previously shown to be safe for the cells and are below the range of doses previously used in similar works (Huang et al., 2012; Hubbert et al., 2002; Tu et al., 2014) .
Immunostaining procedure
For immunocytochemistry, bEnd.3 cells were cultured on glass cover slips in 24 well plates until 90-100% confluence. Cells were then treated with 0.5 and 1 mM of METH in the presence or absence of 100 nM TSA or 1 mM ALC, for 24 h. To evaluate a-tubulin, cells were washed with PBS, fixed during 10 min in methanol and permeabilized in 0.1% Triton X-100 during 10 min. After a blocking of 45 min in 10% NGS (normal goat serum), cells were incubated overnight at 4 C with respective primary antibodies -Mouse antia-tubulin (Sigma, clone AA13 IgG1, #T8203, 1:500) and Mouse anti-acetyl-a-tubulin (Sigma, clone 6-11B-1 IgG2b, #T7451, 1:500). For secondary antibody incubation we used Anti-Mouse IgG Alexa-Fluor 4881 Conjugate (Life Technologies, #A11001, 1:1000) for acetylated form and Anti-Mouse IgG Alexa-Fluor 5681 Conjugate (Life Technologies, #A11004, 1:1000) for total a-tubulin, for 1 h at room temperature in the dark. Coverslips were then mounted onto glass slides with immunomount (Fluorescent Mounting Medium, CA, USA) containing 40 ,6-diamidino-2-phenylindole (DAPI), and then fluorescence microphotographs were captured using Axio Imager Z1 fluorescence microscope (Carl Zeiss, Germany).
Morphometric analysis
Changes observed in a-tubulin acetylation by immunofluorescence assays were evaluated using the Fiji Software version 2.0. A total of four independent experiments were performed. From each coverslip, ten images were blindly captured and analyzed through measurement of fluorescence intensity.
Protein expression analysis by western blot
Confluent bEnd.3 cells cultured in petri dishes were scrapped and lysed with TEN buffer (50 mM Tris-HCl, 2 mM EDTA, 150 mM NaCl, 1% NP-40, supplemented with phosphatases and proteases inhibitors) and then centrifuged at 14,000 g for 15 min at 4 ºC. Protein concentration of the cell lysate was estimated in the supernatant by the Bradford method (Bio-Rad Protein Assay, Munich, Germany). Proteins were loaded at 25mg per lane and resolved by SDS-PAGE on 12% Bis/acrilamide gels and then transferred onto PVDF membranes. After blocking with dry milk 5%, membranes were incubated with mouse anti-acetyl-a-tubulin antibody (Sigma, clone 6-11B-1 IgG2b, #T7451,1:1600). Membranes were washed in Stripping Buffer (RestoreTM Western Blot, Thermo Scientific) and then incubated with mouse anti-a-tubulin (Sigma, clone AA13 IgG1, #T8203, 1:1000). Secondary antibody HRP (horseradish peroxidase)-conjugated were used for 1 h of incubation. Chemiluminescent signal detection was achieved using the Immun-Star HRP kit (Bio-Rad Laboratories, USA). A GS800 densitometer (Bio-Rad) and quantity one 1-D analysis software (v4.6, Bio-Rad) were used for densitometry analysis.
Measurement of HDACs I/II activity
Evaluation of HDACs activity was performed using HDAC-GloTM I/II Assay and Screening System kit (Promega, USA) following provided instructions. This luminescent assay measures relative activity of HDAC enzymes using an acetylated luminogenic peptide susbstrate. When cleaved the substrate is quantified in a reaction using Ultra-GloTM Recombinant Luciferase. Briefly, in each well of 96 multiwell plates, 10,000 bEnd. 3 cells were seeded and treated with ALC and TSA in dilution series: ALC (from 2 mM to 0.125 mM), and TSA (from 500 nM to 3.9 nM). 24 h after treatment, medium was replaced by another without phenol red and HDAC buffer was added, followed by HDACTM I/II reagent. After an incubation of 30 min, luminescence was measured (Gen5 Data Analysis Software, Biotek Instruments, Inc., Synergy 2 (Izasa).
Real time -PCR
Total RNA was extracted from confluent bEnd.3 cells grown in petri dishes, using RNeasy1 Mini Kit (Qiagen, Hilden, Germany). RNA quality was checked by Experion automated electrophoresis system (Bio-Rad Hercules, CA, USA) and cDNA synthesis was performed by Qiagen RT2 HT First Strand cDNA kit using 2.0mg of RNA. RT2 SYBR Green Mastermix was used to amplify and quantify genes expression on a cycler (Bio-Rad iQ5 model). Specific primers were designed for gene relative expression of CDKN1A (F: 50 TGACAGATTTCTATCACTCCAAG30 ; R: 50 TGACCCACAGCAGAAGAG30 ) and HDAC6 (F: 50 GCAGGAGGCAAGTTGATT30 ; R: 50 AAGAAGGGTGTGGAGTGA30 ). Data were analyzed by DDCT method after normalization to GUSB (F: 50 GGTGAAGGTGACAACAACT30 ; R: 50 CTGAATCCTCGTGCTTATTGA30 ) housekeeping gene expression.
Statistical analysis
Results from at least four independent experiments were represented as mean SEM. Significant differences between groups were determined by one-way ANOVA followed by the Sidak's post hoc test. Significance was set at p < 0.05. All analysis were conducted using the software GraphPad Prism1 6.0 for Mac OSX (GraphPad Software, La Jolla, CA).
Results

METH decreased a-tubulin acetylation
The present results show that METH decreased a-tubulin acetylation. Immunofluorescence assays were done for both total and acetylated forms of a-tubulin showing that when bEnd.3 cells were exposed to METH 1 mM, the amount of the acetylated form was significantly reduced (p < 0.01, Fig. 1a and c) . No significant differences were seen in total a-tubulin (Fig. 1b) . This was confirmed by western blot analysis where METH 1 mM reduced significantly the rate of acetylated a-tubulin after 24 h of treatment (p < 0.001, Fig. 1d ).
ALC effectively prevented METH-induced a-tubulin deacetylation
In the present study, we addressed the effect of ALC in preventing METH-induced deacetylation. Since HDAC6 is responsible for the a-tubulin deacetylation, we used a preselected dose of TSA (see Fig. 3a ), a strong inhibitor of HDACs activity. Both ALC and TSA were able to counteract METH-induced deacetylation, as shown in Fig. 2a and b. Our results show that cytoskeleton tubulin from cells pretreated with 1 mM ALC is partially protected from METH-induced damage ( Fig. 2a and b , p < 0.05, METH 1 mM vs. ALC/METH 1 mM). As expected, cells treated simultaneously with TSA and METH presented significantly increased acetylation as shown in Fig. 2b (p < 0.001, TSA/METH 1 mM vs. METH 1 m or vs. the control group). TSA by itself also led to a strong increase in a-tubulin acetylation (p < 0.001, TSA vs. control 100 nM). Further testing through western blot analysis confirmed these results. TSA 100 nM alone or in combination with METH, resulted in a strong acetylation of a-tubulin compared to the control cells or to METH-exposed cells (Fig. 2a-c , p < 0.001 for control vs. TSA 100 nM, control vs. TSA/ METH 1 mM, and METH 1 mM vs. TSA/METH 1 mM). Pretreatment with ALC 1 mM was also seen to be effective in preventing METHinduced deacetylation (Fig. 2c , p < 0.05, METH 1 mM vs. ALC/METH 1 mM). ALC by itself did not significantly differ from the control (Fig. 2b and c, p = 0.42).
ALC is not an effective HDACs inhibitor
Next, we investigated if ALC could act as a HDACs inhibitor. The effect of TSA, a strong inhibitor of HDACs was also assessed. As represented in Fig. 3a , a dose of 100 nM TSA inhibits half of the HDACs activity, while a dose of 500 nM reduced activity to near 20%. ALC, however does not seem to be able to prevent HDACs activity (Fig. 3b) ,the 1 mM dose seems to provide a slight reduction of HDACs activity, but fails to reach significance (p = 0.513, ALC 1 mM vs. control).
ALC prevents METH-induced decrease in CDKN1A gene expression
As ALC does not seem to act as a HDACs inhibitor, we investigated if it could act by downregulation of HDAC6 expression levels. However, as represented in Fig. 4a , the expression of the HDAC6 gene was not affected by METH or ALC, which seems to indicate that METH modulation of HDAC6 occurs at a post-translational level. A common marker of HDACs activity is the inhibition of CDKN1A gene expression due to chromatin remodeling and condensation (Xu et al., 2007) . To evaluate the effect of METH and ALC over HDACs activity, we used RT-PCR to assess CDKN1A gene expression levels. As expected based on the effects described in Sections 3.1 and 3.2, METH-exposure induced a down-regulation of the CDKN1A gene (shown in Fig. 4b , p < 0.001, control vs. METH 1 mM). TSA on the contrary, led to an up-regulation of the CDKN1A gene (Fig. 4b , p < 0.05, control vs. TSA 100 nM) and prevents the down-regulation induced by METH (Fig. 4b , p < 0.001 METH 1 mM vs. TSA/METH 1 mM). Importantly, although ALC by itself did not affect the expression of the CDKN1A gene, a pretreatment with ALC was effective in preventing METH-induced CDKN1A down-regulation (Fig. 4b , p < 0.001, METH vs. ALC/METH 1 mM).
Discussion
The present work shows that METH considerably reduces a-tubulin acetylation in endothelial cells, which is likely to impact cytoskeleton stability, cell motility and polarity, and vesicle transport (Hubbert et al., 2002; Matsuyama et al., 2002) . Importantly, we show that ALC partially prevents METH-induced deacetylation, protecting the endothelial cells and consequently preserving the BBB function. Cytoskeleton microtubules are regulated by several types of conserved posttranslational modifications (Song and Brady, 2014) . Although the biological meaning of such mechanisms is still poorly understood, it was reported that tubulin acetylation increases its stability and half-life, rendering microtubules more resistant to druginduced depolymerization and disassembly (Matsuyama et al., 2002; Szyk et al., 2014) . Previous studies showed that METH impacts actin filaments, leading to actin depolymerization, altered cell shape and local accumulation of condensed actin, which may compromise TJs function and BBB integrity (Park et al., 2013; Young et al., 2014) . Using the bEnd.3 endothelial cell model, we have previously shown that METH-exposure led to a dramatic loss of F-actin integrity concomitant with claudin-5 downregulation and redistribution (Fernandes et al., 2014) . In endothelial cells, these changes at the cytoskeleton level may lead to loss of adhesion and/or relevant restructuring of the endothelium, thus contributing to METH neurotoxicity. Here, in addition, we show that METH reduces microtubule acetylation in endothelial cells. This effect is expected to contribute to BBB disruption, since it was previously shown that induced deacetylation of microtubules was associated with increased vascular permeability (Bogatcheva et al., 2007) , while augmenting microtubule acetylation seems to be concomitant with the inhibition of barrier-disruptive pathways (Gorshkov et al., 2012; Saito et al., 2011) . HDACs modulation by psychostimulants was previously reported. Exposure of adult rats to METH led to altered expression patterns of several HDACs, including HDAC1 and HDAC2 Martin et al., 2012) , and HDAC6, HDAC8-HDAC11, SIRT2, SIRT5 and SIRT6 (Omonijo et al., 2014) . These expression patterns seem to depend on the METH dose and period of exposure. Similarly, cocaine self-administration was shown to induce increased expression of several HDACs (Host et al., 2011) . In the present study, to verify if METH-induced deacetylation of a-tubulin was a result of HDACs modulation by METH, we used the HDACs inhibitor TSA (Dompierre et al., 2007) . Our results evidence that TSA not only prevents METH-induced deacetylation, as it strongly promotes a-tubulin acetylation also in METH-exposed endothelial cells. TSAmediated hyperacetylation was shown to increase the lifespan of neuronal cultures, and a number of studies reported the anti-inflammatory and neuroprotective effects of hyperacetylation both in vitro or in vivo models of ischemic stroke (Chuang et al., 2009; Harrison and Dexter, 2013) and toxicity (Agudelo et al., 2011) . TSA was also used as a neuroprotective agent in several models of Parkinsonism (Harrison and Dexter, 2013 ), Huntington's disease, Alzheimer's disease and other neurological diseases (Chuang et al., 2009 ). In the oncology context, TSA has been intensively studied. Of note, a recent study showed that TSA inhibits cancer invasion through MMPs inhibition associated with HDAC2 suppression (Wang et al., 2013 ). As we have recently shown that METH disrupts actin integrity through MMP-9 modulation, it is possible that MMPs inhibition may also contribute to prevent METH-induced deacetylation of tubulin. However, as prolonged treatment with TSA may lead to neuronal cell toxicity, care should be taken when TSA is used for neuroprotective purposes (Chuang et al., 2009 ). Since we have recently shown that ALC counteracts the effect of METH in MMP-mediated toxicity, we have also addressed the possible role of ALC in preventing METH-modulation of HDACs. As a result, in the present work, we show that 1 mM ALC was able to prevent METH-induced deacetylation of a-tubulin. A previous report postulated that ALC had the potential to directly inhibit HDACs activity in several cell types possibly by chelating and removing Zn2+ from the active site of the HDAC enzyme (Huang et al., 2012) . However, here, we could not observe a significant effect of ALC on HDACs activity. Of note, the doses used by Huang et al. (2012) were 5 and 10 fold higher than the 1 mM dose shown here to efficiently prevent tubulin deacetylation. In addition, neither METH nor ALC led to altered levels of HDAC6 gene expression, which seems to indicate that both ALC-and METH-modulation of HDAC6 activity may occur in a post-translation way, as described for TSA (Xu et al., 2007) . Despite the previously reported protective properties of ALC (Pettegrew et al., 2000) , its action at the cytoskeleton level is still poorly explored. We have recently shown that ALC effectively prevents METH-induced loss of alignment in endothelial actin filaments, through ILK mediated release of MMP-9 (Fernandes et al., 2014) . Of note, ILK was also shown to mediate MMP-9-release through regulation of glycogen synthase (GSK)-3b activity (for review see McDonald et al., 2008) , while GSK3b is known to interact and colocalize with HDAC6, enhancing its activity (Li et al., 2013) .
Since it was reported that ALC antagonizes GSK-3b, arresting microtubule-associated protein tau hyperphosphorylation in Alzheimer's disease (Jiang et al., 2011) , it is possible that ALC mediation of HDAC6 activity may also occur through GSK-3b inhibition. This putative mechanism of action is essentially different from that of TSA that may inhibit HDCAs by binding to zinc in their catalytic site (Finnin et al., 1999) . In addition to hyperacetylation of the respective substrates, HDACs inhibition is also known to lead to increased histone acetylation and consequent chromatin remodeling (Li et al., 2013; Xu et al., 2007) . Under TSA treatment, chromatin relaxation is known to increase the expression of CDKN1A (cyclin-dependent kinases inhibitor, or p21) gene (Blagosklonny et al., 2002; Hrabeta et al., 2014; Ocker and Schneider-Stock, 2007; Xu et al., 2007) . As such, CDKN1A (p21) expression is frequently used as a marker of HDAC inhibition (Harrison and Dexter, 2013; Huang et al., 2012; Xu et al., 2007) . As expected our results show that TSA promotes the overexpression of CDKN1A. Opposing to this, in METHexposed cells, CDKN1A expression was clearly reduced, which was counteracted by ALC and TSA. These results show that in the presence of METH, both ALC and TSA seem to maintain CDKN1A expression at levels that are not significantly different from the control. However, contrarily to TSA, ALC does not trigger CDKN1A overexpression, which has been repeatedly associated with cell cycle arrest, senescence and cell death (reviewed by Xu et al., 2007) . In that sense, the protection afforded through ALC may be more effective and lead to less severe side effects.
In summary, we show here for the first time that METH promotes deacetylation of atubulin, which is likely to impact the structure of microtubules at the endothelial cytoskeleton and disturb the BBB function. Additionally, we show also that ALC is able to prevent METHinduced deacetylation, providing effective protection of microtubules acetylation, without risking the critical consequences of HDACs inhibition (Fig. 5) . Although further investigation is still needed, HDACs regulation may become a new therapeutic target for ALC.
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